Carl Zeiss Meditec Full Year 2023 Earnings: EPS Beats Expectations

editorial-team@simplywallst.com (Simply Wall St)
1 min read
0
In this article:

Carl Zeiss Meditec (ETR:AFX) Full Year 2023 Results

Key Financial Results

  • Revenue: €2.09b (up 9.8% from FY 2022).

  • Net income: €290.4m (down 1.2% from FY 2022).

  • Profit margin: 14% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses.

  • EPS: €3.25 (down from €3.29 in FY 2022).

revenue-and-expenses-breakdown
XTRA:AFX Revenue and Expenses Breakdown December 19th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Carl Zeiss Meditec EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%.

The primary driver behind last 12 months revenue was the Ophthalmic Devices (Including Surgical Ophthalmology) segment contributing a total revenue of €1.58b (75% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to €420.3m (46% of total expenses). Explore how AFX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany.

Performance of the German Medical Equipment industry.

The company's shares are up 14% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Carl Zeiss Meditec's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Advertisement

Recommended Stories